A prediction model for central venous catheter-related thrombosis in patients with newly-diagnosed acute myeloid leukemia: A derivation cohort analysis

Perek, Shay; Khatib, Alaa; Izhaki, Niv; Khalaila, Ali Sleman; Brenner, Benjamin; Horowitz, Netanel A.

doi:10.1016/j.ejim.2022.04.025

Cited by 9 publications

(4 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further complicating comparisons to solid cancer patients, all AML patients treated with intensive induction or consolidation chemotherapy receive CVCs, a well-known risk factor for thrombosis 45 and indeed frequently experience CVC-related VTE. 38 Notably, the adverse impact of VTE on survival in cancer patients is at least partly attributable to a more aggressive biology of the underlying malignancy. 43,45 In AML, this may manifest itself via non-CVC-related VTE not provoked by vessel cannulation.…”

Section: Discussionmentioning

confidence: 99%

“…Martella et al 37 described a 22% VTE prevalence in newly diagnosed AML and high‐risk MDS patients over a follow‐up period of 44 months, with the majority of events occurring within the first 100 days from AML diagnosis. Finally, Perek et al 38 focused on CVC‐related VTE in newly‐diagnosed AML patients including APL and reported a cumulative incidence of 10.1% with a median time from AML diagnosis to VTE of 12.5 days. Our observed VTE incidence of 7.3% in newly diagnosed AML patients within 3 months of admission for induction chemotherapy appears plausible within this context.…”

Section: Discussionmentioning

confidence: 99%

“…However, study population sizes of AML patients have so far been limited and prognostic implications of VTE may simply be more difficult to detect in AML patients due to higher mortality rates compared to solid cancer patients. Further complicating comparisons to solid cancer patients, all AML patients treated with intensive induction or consolidation chemotherapy receive CVCs, a well‐known risk factor for thrombosis 45 and indeed frequently experience CVC‐related VTE 38 . Notably, the adverse impact of VTE on survival in cancer patients is at least partly attributable to a more aggressive biology of the underlying malignancy 43,45 .…”

Section: Discussionmentioning

confidence: 99%

“…period of 44 months, with the majority of events occurring within the first 100 days from AML diagnosis. Finally, Perek et al38 focused on CVC-related VTE in newly-diagnosed AML patients including APL and reported a cumulative incidence of 10.1% with a median time from AML diagnosis to VTE of 12.5 days. Our observed VTE incidence of 7.3% in newly diagnosed AML patients within 3 months…”

mentioning

confidence: 99%

See 3 more Smart Citations

Early‐onset venous thromboembolisms in newly diagnosed non‐promyelocytic acute myeloid leukemia patients undergoing intensive induction chemotherapy

Koschade

Stratmann

Steffen

et al. 2023

European J of Haematology

View full text Add to dashboard Cite

Objectives and Methods Venous thromboembolic (VTE) events are emerging as frequent complications in acute myeloid leukemia (AML); however, there is insufficient data regarding epidemiology, risk factors, and impact on outcomes. The optimal approach to balance risks of thrombosis and hemorrhage remains unclear. This retrospective single‐center study in AML patients undergoing induction chemotherapy between 2007 and 2018 assessed incidence, risk factors, features, and outcomes of early‐onset VTE. Results 423 patients (median age 59 years) were enrolled. VTE was diagnosed in 31 patients (7.3%) within 3 months of admission. The median time to VTE was 3 days. Non‐central venous catheter (CVC)‐related VTE occurred in 19 patients (61%). Main risk factor for VTE was leukocytosis at admission, independent of platelet counts/INR. Four patients (13%) exhibited VTE recurrence. No deaths directly related to VTE or major bleeding events associated with platelet‐adjusted anticoagulation in patients with VTE were recorded. There was no clear impact of VTE on 1‐year overall survival; however, non‐CVC‐related VTE may be associated with adverse outcomes. Conclusions Early‐onset VTE is a common complication in newly diagnosed AML patients admitted for induction chemotherapy. Leukocytosis is an independent VTE risk factor. The potentially adverse impact of non‐CVC‐related VTE merits further study.

show abstract